Consolidation immunotherapy after concurrent chemoradiotherapy enabling conversion surgery for stage IIIB pulmonary NUT carcinoma: a case report and literature review
Abstract
BackgroundPulmonary NUT carcinoma is a rare, highly aggressive malignancy. Its clinical presentation is nonspecific, so most patients are diagnosed at an advanced stage and face a very poor prognosis. At present, no standard treatment regimen has been established.Case presentationWe report a 45-year-old man diagnosed with stage cT4N2M0 (IIIB) pulmonary NUT carcinoma. He received induction chemotherapy with etoposide plus cisplatin (EP regimen) combined with atezolizumab, followed by concurrent chemoradiotherapy (with immunotherapy withheld during radiotherapy), then consolidative chemoimmunotherapy and surgery. Postoperative pathology demonstrated a pathological complete response (pCR), and the patient has remained alive for more than 49 months since diagnosis with good treatment tolerance.Literature review and discussionWe performed a pooled analysis of 72 cases of pulmonary NUT carcinoma reported since 2015. The median overall survival (OS) was 5.6 months. Patients who underwent surgical treatment had improved survival compared with those who did not. Immunotherapy was associated with significantly improved OS.ConclusionIn carefully selected patients with locally advanced pulmonary NUT carcinoma, individualized multimodality treatment can achieve a pCR and prolonged survival, underscoring the importance of accurate molecular diagnosis, early multidisciplinary management, and reassessment of surgical resectability. Nevertheless, this treatment sequence remains hypothesis-generating and requires validation in prospective studies.
Related
- Efficacy and safety analysis of consolidation immunotherapy following definitive concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
- Clinical efficacy and safety of immunotherapy after concurrent chemoradiotherapy in advanced esophageal cancer.
- Rapid disease progression during adjuvant chemotherapy following concurrent chemoradiotherapy and radical resection for rectal sarcomatoid carcinoma: a case report and literature review
- Sequential chemoradiotherapy vs. radiotherapy alone or concurrent chemoradiotherapy after radical resection of stage IA2–IIA1 cervical cancer: a retrospective cohort study
- A Systematic Review and Meta-Analysis: Does Molecular Hydrogen Exert Radioprotective Effects Without Compromising the Antitumor Efficacy of Radiotherapy or Concurrent Chemoradiotherapy?
BibTeX
@article{zhong2026consolidation,
title = {{Consolidation immunotherapy after concurrent chemoradiotherapy enabling conversion surgery for stage IIIB pulmonary NUT carcinoma: a case report and literature review}},
author = {Liqiang Zhong and Li Xu and Qiu Wang and Ying Yin and Min Tang and Jian Jiang and Jingbo Wu},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1970432},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1970432},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Consolidation immunotherapy after concurrent chemoradiotherapy enabling conversion surgery for stage IIIB pulmonary NUT carcinoma: a case report and literature review
AU - Liqiang Zhong
AU - Li Xu
AU - Qiu Wang
AU - Ying Yin
AU - Min Tang
AU - Jian Jiang
AU - Jingbo Wu
PY - 2026
DA - 2026/11/09
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1970432
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1970432
AB - BackgroundPulmonary NUT carcinoma is a rare, highly aggressive malignancy. Its clinical presentation is nonspecific, so most patients are diagnosed at an advanced stage and face a very poor prognosis. At present, no standard treatment regimen has been established.Case presentationWe report a 45-year-old man diagnosed with stage cT4N2M0 (IIIB) pulmonary NUT carcinoma. He received induction chemotherapy with etoposide plus cisplatin (EP regimen) combined with atezolizumab, followed by concurrent chemoradiotherapy (with immunotherapy withheld during radiotherapy), then consolidative chemoimmunotherapy and surgery. Postoperative pathology demonstrated a pathological complete response (pCR), and the patient has remained alive for more than 49 months since diagnosis with good treatment tolerance.Literature review and discussionWe performed a pooled analysis of 72 cases of pulmonary NUT carcinoma reported since 2015. The median overall survival (OS) was 5.6 months. Patients who underwent surgical treatment had improved survival compared with those who did not. Immunotherapy was associated with significantly improved OS.ConclusionIn carefully selected patients with locally advanced pulmonary NUT carcinoma, individualized multimodality treatment can achieve a pCR and prolonged survival, underscoring the importance of accurate molecular diagnosis, early multidisciplinary management, and reassessment of surgical resectability. Nevertheless, this treatment sequence remains hypothesis-generating and requires validation in prospective studies.
SN - 2234-943X
ER -